ArticleEJHaem2026

A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.

Kim Saverno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.